CALL US: 206.533.3854
CALL US  206.533.3854
Full color aeon logo
'bug for today: staphylococcus aureus' by estherase is licensed under CC BY-SA 2.0

Federal Circuit Reverses Patent Board on “Obviousness”

Federal Circuit
Reverses PTAB ruling
On obviousness

The Federal Circuit has reversed a decision by the US Patent and Trademark Office’s (USPTO’s) Patent Trial and Appeal Board (PTAB or Board) that patent claims involving antibiotic-resistant bacteria were unpatentable as obvious.

The case involved a patent application by the University of Strathclyde in Glasgow, Scotland.

The court noted that

Methicillin-resistant Staphylococcus aureus (MRSA), and other Gram-positive bacteria that have developed resistance to antibiotics, are “known to cause health problems, particularly in the hospital environment.”

The Centers for Disease Control and Prevention (CDC) have reported that “Approximately 5% of patients in U.S. hospitals carry MRSA in their nose or on their skin.”

MRSA can cause:

  • bloodstream infections
  • pneumonia
  • surgical site infections
  • sepsis
  • death

It is usually spread by direct contact with an infected wound or via the hands of healthcare providers.

The University’s patent application explained that

effective methods of controlling transmission of and rising infection rates from antibiotic-resistant bacteria are “becoming one of the most significant problems within the healthcare industry.” … This is due, in part, to the “availability of few effective sterili[z]ation methods for environmental decontamination” of air and surfaces

Previous photoinactivation methods have used light in combination with a photosensitizer to kill bacteria. However, as the court notes, this method

suffers from “the significant practical disadvantage that photosensiti[z]ing agents must be applied to the bacteria that are to be inactivated.”


Scientists at the University of Strathclyde, recognizing this practical disadvantage, developed a method for photoinactivating antibiotic-resistant bacteria like MRSA without using a photosensitizing agent. Through numerous experiments, the inventors found that “[e]xposing [certain] bacteria to blue light, or white light containing blue light” having a wavelength in the region of 400–500 nm, “stimulate[s] an inactivation process.”

Clear-Vu Lighting petitioned for inter partes review of four claims of the University’s patent, including on the grounds that they were obvious in light of prior art. The PTAB agreed in part.

A person having ordinary skill in the art (PHOSITA), or “skilled artisan,” is a legal construct used to determine whether a claimed invention is “obvious” and thus unpatentable. Such a theoretical person is considered to have the skills and knowledge common in a technical or scientific field.

As the court noted,

Whether the prior art discloses a claim limitation, whether a skilled artisan would have been motivated to modify or combine teachings in the prior art, and whether she would have had a reasonable expectation of success in doing so are questions of fact.

Given that the prior art relevant to the University’s invention at issue neither “teaches or suggests inactivation of any bacteria without using a photosensitizer,” the court concluded that a skilled artisan would not omit a photosensitizer when combining these prior art methods – especially since a prior photosensitizer-free method didn’t work:

Thus, not only is there a complete lack of evidence in the record that any bacteria were inactivated after exposure to 407–420 nm blue light without using a photosensitizer, there is also evidence showing that others had failed to inactivate MRSA—one of the claimed Gram-positive bacteria—without using a photosensitizer, despite experimenting with different light doses and different wavelength ranges of blue light. We have found that such failures undermine a finding of a reasonable expectation of success.


The Board found that a skilled artisan would have expected that MRSA could be inactivated by blue light without using a photosensitizer due to the presence of at least some amount of naturally produced porphyrin in the bacteria. We disagree. The only support for such a finding is pure conjecture coupled with hindsight reliance on the teachings in the ’706 patent.

Therefore, the court reversed the PTAB’s obviousness determination.

Just like the haiku above, we like to keep our posts short and sweet. Hopefully, you found this bite-sized information helpful. If you would like more information, please do not hesitate to contact us here.

Related Articles

Federal Circuit Allows “Trump Too Small” Trademark

Federal Circuit:
First Amendment allows the
“Trump Too Small” trademark

Read More

When is trademark generic?

Generic trademarks:
Won’t be granted to start with,
And can be cancelled

Read More

AEON Law Founder Named Crypto “Trailblazer” by the National Law Journal

Adam Philipp, the founder of AEON Law, has been recognized among the leading practitioners of blockchain, cryptocurrency, and fintech law by the National Law Journal.

Read More

Stay Informed

Sign up to receive Patent Poetry—a monthly roundup of key IP issues in our signature haiku format. Four articles (only 68 syllables); zero hassle.



International IP Protection